How to control the solid form of your API for higher bioavailability and easier drug development
In addition to efficacy and toxicological evaluation, the bioavailability of an Active Pharmaceutical Ingredient (API) plays a critical role in the path of drug development.
However, 90% of New Chemical Entities are poorly water soluble, which results in low bioavailability. One critical character that contributes to the drug bioavailability is its solid form which can be expressed either as a salt, a co-crystal or the parent compound. Furthermore the polymorphism of the form of interest is key for a drug development.
The selection the most favorable solid form of your API in early phase will not only expedite your drug development process, but also enhance your IP position in the competitive landscape.
Watch this webinar presented by Seqens team of experts to understand how you can benefit from early solid form screening and related activities.
During this webinar you will learn:
- Insights from industrial practitioners on API solid form development
- Why form screening at early stage is critical to avoid issues at later phases of development
- Key considerations in determining best solid form moving forward
- How to efficiently expedite your solid state development activity
Speakers:
- Hong Shen, PhD Analytical Development Director
- Julien Leroudier, PhD, Manager R&D Cristalization
- Gautier Decock , CRDO Managing Director
